Last reviewed · How we verify
RSV F subunit 45 μg MF59 adjuvant — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
RSV F subunit 45 μg MF59 adjuvant (RSV F subunit 45 μg MF59 adjuvant) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RSV F subunit 45 μg MF59 adjuvant TARGET | RSV F subunit 45 μg MF59 adjuvant | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RSV F subunit 45 μg MF59 adjuvant CI watch — RSS
- RSV F subunit 45 μg MF59 adjuvant CI watch — Atom
- RSV F subunit 45 μg MF59 adjuvant CI watch — JSON
- RSV F subunit 45 μg MF59 adjuvant alone — RSS
Cite this brief
Drug Landscape (2026). RSV F subunit 45 μg MF59 adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/rsv-f-subunit-45-g-mf59-adjuvant. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab